Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?

Sascha Gerdes¹, Joerg Albrecht^{2

3}

Affiliations

¹ Psoriasis-Center Kiel, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Division of Dermatology, Department of Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL, USA.
³ Division of Dermatology, Department of Otorhinolaryngology, Rush Medical College, Chicago, IL, USA.

Comment

Sascha Gerdes et al. Br J Dermatol. 2022 Apr.

. 2022 Apr;186(4):603-604.

doi: 10.1111/bjd.20959.

Sascha Gerdes¹, Joerg Albrecht^{2

3}

¹ Psoriasis-Center Kiel, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Division of Dermatology, Department of Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL, USA.
³ Division of Dermatology, Department of Otorhinolaryngology, Rush Medical College, Chicago, IL, USA.

No abstract available

Comment on

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, Edwards H, Garcet S, Li X, Dizier B, Maroof A, Watling M, El Baghdady A, Baeten D, Ionescu L, Shaw S. Oliver R, et al. Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34687214 Free PMC article. Clinical Trial.

1. Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs 2021; 81:1751-62.
1. Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther 2019; 19:45-54.
1. Oliver R, Krueger JG, Glatt S et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol 2022; 186:652-63.
1. Reich K, Warren RB, Lebwohl M et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 385:142-52.
1. Pavlova A, Sharafutdinov I. Recognition of Candida albicans and role of innate type 17 immunity in oral candidiasis. Microorganisms 2020; 8:1340.